Adlai Nortye Ltd. (ANL)Healthcare | Biotechnology | North Brunswick, United States | NasdaqGM
9.24 USD
-0.63
(-6.383%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 9.24 |
Hot Take ↕ | July 11, 2026, 5:28 a.m. EDT
The immediate outlook is clouded by severe structural damage to the business model. The company is burning through cash at an alarming rate, with free cash flow plummeting to nearly -$38 million and operating cash flow at -$33 million. This hemorrhaging of capital is compounded by a balance sheet that is already insolvent on paper, showing negative book value and a current ratio well below 1.0, indicating an inability to cover short-term liabilities without further dilution. While the stock recently rallied on a $150 million private placement and positive analyst sentiment, these are classic distress financing maneuvers for a biotech firm with no revenue and negative earnings. The recent price action shows volatility but lacks the sustained momentum required for a bullish entry, as the underlying fundamentals suggest the market is pricing in a high probability of failure or further dilution rather than sustainable growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.261237 |
| MSTL_116 | 0.279170 |
| MSTL_77_116 | 0.370249 |
| AutoETS | 0.534948 |
| MSTL | 0.597628 |
| MSTL_77 | 0.669849 |
| AutoARIMA | 0.811555 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 11.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.086 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.156 |
| Market Cap | 595,036,928 |
| Forward P/E | -24.71 |
| Beta | 1.11 |
| Website | https://www.adlainortye.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 5.5364237 |
| Address1 | New Jersey Biotechnology Dev Ctr |
| Address2 | 2nd floor 685 US Hwy 1 |
| All Time High | 19.3 |
| All Time Low | 0.879 |
| Ask | 11.48 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 257,300 |
| Average Daily Volume3 Month | 299,450 |
| Average Volume | 299,450 |
| Average Volume10Days | 257,300 |
| Beta | 1.111 |
| Bid | 6.84 |
| Bid Size | 2 |
| Book Value | -0.208 |
| City | North Brunswick |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.24 |
| Current Ratio | 0.646 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.86 |
| Day Low | 8.94 |
| Display Name | Adlai Nortye |
| Earnings Timestamp End | 1,755,864,000 |
| Earnings Timestamp Start | 1,754,650,740 |
| Ebitda | -34,935,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.078 |
| Enterprise To Revenue | 77.403 |
| Enterprise Value | 387,015,456 |
| Eps Current Year | -0.29667 |
| Eps Forward | -0.374 |
| Eps Trailing Twelve Months | -1.11 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.6472 |
| Fifty Day Average Change | -2.4071999 |
| Fifty Day Average Change Percent | -0.20667627 |
| Fifty Two Week Change Percent | 553.6424 |
| Fifty Two Week High | 17.25 |
| Fifty Two Week High Change | -8.01 |
| Fifty Two Week High Change Percent | -0.46434784 |
| Fifty Two Week Low | 0.879 |
| Fifty Two Week Low Change | 8.361 |
| Fifty Two Week Low Change Percent | 9.511946 |
| Fifty Two Week Range | 0.879 - 17.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,695,994,200,000 |
| Float Shares | 18,427,723 |
| Forward Eps | -0.374 |
| Forward P E | -24.705881 |
| Free Cashflow | -37,687,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 109 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 5,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.24549 |
| Implied Shares Outstanding | 64,397,938 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-09-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey. |
| Long Name | Adlai Nortye Ltd. |
| Market | us_market |
| Market Cap | 595,036,928 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1830112145 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -35,528,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 635,607,644 |
| Number Of Analyst Opinions | 5 |
| Open | 9.86 |
| Operating Cashflow | -33,452,000 |
| Operating Margins | -3.3048 |
| Payout Ratio | 0.0 |
| Phone | 848 230 7430 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.24 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 9.87 |
| Price Eps Current Year | -31.145718 |
| Price Hint | 2 |
| Price To Book | -44.423077 |
| Price To Sales Trailing12 Months | 119.007385 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.63 |
| Regular Market Change Percent | -6.38298 |
| Regular Market Day High | 9.86 |
| Regular Market Day Low | 8.94 |
| Regular Market Day Range | 8.94 - 9.86 |
| Regular Market Open | 9.86 |
| Regular Market Previous Close | 9.87 |
| Regular Market Price | 9.24 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 234,194 |
| Return On Assets | -0.42215002 |
| Return On Equity | -4.14007 |
| Revenue Growth | 1.781 |
| Revenue Per Share | 0.156 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 58,734,604 |
| Shares Percent Shares Out | 0.051799998 |
| Shares Short | 3,335,395 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,208,854 |
| Short Name | Adlai Nortye Ltd. |
| Short Percent Of Float | 0.0573 |
| Short Ratio | 24.3 |
| Source Interval | 15 |
| State | NJ |
| Symbol | ANL |
| Target High Price | 46.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 28.6 |
| Target Median Price | 23.0 |
| Total Cash | 8,963,000 |
| Total Cash Per Share | 0.224 |
| Total Debt | 26,376,000 |
| Total Revenue | 5,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.711095 |
| Two Hundred Day Average Change | 2.528905 |
| Two Hundred Day Average Change Percent | 0.3768245 |
| Type Disp | Equity |
| Volume | 234,194 |
| Website | https://www.adlainortye.com |
| Zip | 8,902 |